Company profile

CARDINAL HEALTH INC

NYSE:CAHOther Pharmaceuticals

Drug pipeline (6)

AssetStageRevenueTrialsStatus
AMMONIA N-13approved0
FLUDEOXYGLUCOSE F-18approved0
SODIUM FLUORIDE F-18approved0
SODIUM IODIDE I-123approved0
SODIUM IODIDE I-131approved0

Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.

Clinical trials (3)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT02857608phase2withdrawn2016-09-012017-08-01Cardinal Health 414, LLCA Prospective, Open-Label, Multi-center Comparison of Lymphoseek Identified Lymph Nodes and Clinically Identified Lymph Nodes of Subjects With Known Cancer of the Anus
NCT02509598phase2completed2015-08-012019-03-06Cardinal Health 414, LLCA Study of Lymphoseek® as a Lymphoid Tissue Targeting Agent in Pediatric Patients With Melanoma, Rhabdomyosarcoma, or Other Solid Tumors Who Are Undergoing Lymph Node Mapping
NCT02509585phase2terminated2016-01-012017-07-01Cardinal Health 414, LLCA Trial of Comparing the Pathology Status of Lymphoseek®-Identified Sentinel Lymph Nodes Relative to the Pathological Pathology Status of Nonsentinel Lymph Nodes in Nodal Staging of Subjects With Known Cancer of the Cervix Who Are Undergoing Lymph Node Dissection

FDA applications (8)

ApplicationTypeApplicantProducts
ANDA 078809ANDACARDINAL HEALTH 414 LLC CARDINAL HEALTH NUCLEAR PHARMACY SERVICES
ANDA 203603ANDACARDINAL HEALTH 414 LLC CARDINAL HEALTH NUCLEAR PHARMACY SERVICES
ANDA 203700ANDACARDINAL HEALTH 414 LLC
ANDA 203780ANDACARDINAL HEALTH 414 LLC CARDINAL HEALTH NUCLEAR PHARMACY SERVICES
ANDA 213615ANDACARDINAL HEALTH 414 LLC